Search

25 years of OCT

David Huang first described optical coherence tomography (OCT) in 1991, in his seminal paper on the subject in Science. This method developed the work of others on ophthalmic interferometry, which essentially showed that measuring reflected light could be used to...

Initiatives in macular service provision

A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...

What’s next in retinal imaging? Faster, deeper and full-on

Fast-evolving technological leaps are opening the way toward clinically useful ocular coherence angiography, generating 3-dimensional microvasculature maps without intravenous dye injection, as well as whole-eye imaging, handheld patient-operated optical coherence tomography (OCT) devices and, for challenging vitreoretinal procedures, integrated intraoperative...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...

What’s new in wet AMD papers?

Paper presentations on neovascular (‘wet’) age-related macular degeneration (AMD) from the 16th European Society of Retina Specialists Congress, Copenhagen, September 2016, outline recent research directions evaluating the impact of vision loss on key health domains, patient preferences in the process...

Intravitreal injections delivered by ophthalmic clinical nurse specialists

Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...

Diary from my elective: a Parisian experience

The author explains how a research institute’s dedication to multidisciplinary collaboration helped him to discover a passion for academic ophthalmology. The elective aspect to the final year of a medical degree, through its change of scenery and immersion into another...

100 years of insulin

*Joint first authors The centenary of the discovery of insulin is a time to celebrate one of the most significant scientific discoveries of the 20th century. Background Before 1923, Type 1 diabetes mellitus [T1DM] resulted in death from severe ketoacidosis...

Nano-ophthalmology paves a new path in the future of eyecare

Introduction The treatments of ocular conditions in the field of ophthalmology varies from topical to surgical procedures. The field of nanotechnology is one of the fast-growing fields of medicine, which plays an important role in turning the impossibilities of the...

Eye research: where next?

Eye research in the UK is underfunded relative to other areas of medical research and general awareness of sight loss and its prevention remains poor, messages that were reinforced in presentations and discussions during a recent research summit meeting in...